姑息性微创远端胰腺切除术治疗意外转移性胰腺导管腺癌的肿瘤学结局
该单中心回顾性研究纳入46例术中意外发现左侧胰腺导管腺癌转移的患者,比较姑息性微创远端胰腺切除术(19例)与微创活检(27例)的结局。
核心结论
- 对经选择的意外转移性胰腺导管腺癌患者,姑息性微创远端胰腺切除术可能改善生存并促进化疗延续。
研究设计与样本
- 单中心回顾性研究,纳入2005至2019年术中意外发现左侧胰腺导管腺癌转移的46例患者。
- 19例接受姑息性微创远端胰腺切除术,27例仅接受微创活检。
- 比较两组人口学、临床、手术数据及生存率。
临床怎么用
- 对术中意外发现转移的左侧胰腺导管腺癌患者,在充分评估后可考虑姑息性微创远端胰腺切除术以促进化疗完成。
- 完成一线化疗和维持化疗超过12个月与生存改善相关,应重视化疗延续性。
局限性
- 样本量小(共46例)。
- 存在潜在选择偏倚。
- 研究为单中心回顾性设计,结果外推受限。
- 需更大规模前瞻性多中心研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefits of palliative minimally invasive distal pancreatectomy for patients with unexpectedly metastatic pancreatic ductal adenocarcinoma have not been previously studied. This retrospective study compared the outcomes of palliative minimally invasive distal pancreatectomy with those of minimally invasive biopsy in these patients. METHODS: We reviewed the records of 46 patients with unexpected metastasis of left-sided pancreatic ductal adenocarcinoma that were discovered during surgery between 2005 and 2019. Nineteen patients underwent palliative resection (minimally invasive distal pancreatectomy group), whereas 27 patients underwent only minimally invasive biopsy (minimally invasive biopsy group). Demographic, clinical, and operative data, as well as survival rates, were compared between the 2 groups. RESULTS: Major complications (Clavien-Dindo grade ≥3) were comparable between the 2 groups (11.8% vs 5.6%; P = .603). Postoperative chemotherapy was administered to 84.2% of the minimally invasive distal pancreatectomy group and 77.8% of the minimally invasive biopsy group (P = .716). The minimally invasive distal pancreatectomy group had a higher completion rate of first-line palliative chemotherapy (42.9% vs 8.7%; P = .007) and a higher 2-year survival rate (36.8% vs 18.8%; P = .004). In multivariate analysis, survival was associated with completion of first-line chemotherapy (hazard ratio: 2.962; P = .003) and maintenance chemotherapy for over 12 months (hazard ratio: 2.339; P = .010). Gastric outlet obstruction was less prevalent in the minimally invasive distal pancreatectomy group (5.3% vs 25.9%, P = .037). CONCLUSION: Palliative minimally invasive distal pancreatectomy may improve survival and facilitate the continuation of chemotherapy in selected patients with unexpected metastatic pancreatic ductal adenocarcinoma. However, the small sample size and potential selection bias limit the generalizability of these findings. Larger, prospective, multicenter studies are needed to confirm the role of minimally invasive distal pancreatectomy and to establish optimal management strategies for these patients.
引用
- Park Y, Hwang DW, Lee JH, et al. Oncological outcomes of palliative minimally invasive distal pancreatectomy for unexpected metastatic pancreatic ductal adenocarcinoma: A single-center experience. Surgery. 2025. PMID: 40138876. doi:10.1016/j.surg.2025.109331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。